ArticleAntimicrobial agents and chemotherapy2013
In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.Hepatology (Baltimore, Md.) · 2015Trial
- Article
- Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C.Diagnostics (Basel, Switzerland) · 2022Article
- Prevalence and Pattern of Resistance in NS5A/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of São Paulo, Brazil.Infection and drug resistance · 2021Article
- Article
- Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.Infection · 2018Review
- Article
- The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus.Virus evolution · 2018Article
- Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon.The Journal of general virology · 2017Article
- Article
- Article
- Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.PloS one · 2017Article
- Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview.Journal of clinical and translational hepatology · 2016Review
- Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.Hepatology international · 2016Review
- NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection.The Journal of infectious diseases · 2016Article
- Article
- Genotype 3: Treat now or wait for something better?Clinical liver disease · 2015Review
- Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.Antimicrobial agents and chemotherapy · 2014Article
- Resistance patterns associated with HCV NS5A inhibitors provide limited insight into drug binding.Viruses · 2014Review
- Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.Antimicrobial agents and chemotherapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The NS5A replication complex inhibitor daclatasvir (DCV; BMS-790052) inhibits hybrid replicons containing hepatitis C virus (HCV) genotype 3a (HCV3a) NS5A genes with 50% effective concentrations (EC(50)s) ranging from 120 to 870 pM. Selection studies with a hybrid HCV3a replicon identified NS5A residues 31 and 93 as sites for DCV-selected resistance. Our results support the potential use of DCV as a component in combination therapies for HCV3a chronic infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.